Goodwin Procter advised Ocata Therapeutics (NASDAQ: OCAT) in the completion of its sale to Astellas Pharma for approximately $380 million in cash in a two-step tender offer transaction. At $8.50 per share, the offer price was a 79% premium to Ocata’s trading price on the last trading day prior to the signing date of the definitive merger agreement on November 9, 2015.
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Ocata's most advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata's intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Astellas Pharma Inc., based in Tokyo, Japan, is dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas focuses on urology, oncology, immunology, nephrology and neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities.
The Goodwin team was led by partners Mitch Bloom, James Matarese, Andrew Goodman and associate Bill Collins (Technology and Life Science), and included associates Lillian Kim, Dana Antakly and Evan Segal (Corporate); associate Alexandra Denniston (Employee Benefits); partner Deborah Birnbach, associate Ezekiel Hill and senior attorney Ai Tajima (Securities Litigation); partner Andrea Murino and counsel Todd Hahn and Kirby Lewis (Antitrust); partner Janet Andolina and associate Adam Romig (Tax).